Market closedNon-fractional
Inozyme Pharma/INZY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX
About Inozyme Pharma
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.
Ticker
INZY
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
Boston, United States
Employees
59
Website
www.inozyme.com
Inozyme Pharma Metrics
BasicAdvanced
$358M
Market cap
-
P/E ratio
-$1.37
EPS
1.54
Beta
-
Dividend rate
Price and volume
Market cap
$358M
Beta
1.54
Financial strength
Current ratio
14.052
Quick ratio
13.393
Long term debt to equity
38.457
Total debt to equity
39.243
Interest coverage (TTM)
-18.85%
Management effectiveness
Return on assets (TTM)
-32.56%
Return on equity (TTM)
-69.41%
Valuation
Price to book
3
Price to tangible book (TTM)
3
Price to free cash flow (TTM)
-4.205
Growth
Earnings per share change (TTM)
-13.39%
3-year earnings per share growth (CAGR)
-27.56%
What the Analysts think about Inozyme Pharma
Analyst Ratings
Majority rating from 8 analysts.
Inozyme Pharma Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$23M
8.37%
Profit margin
0.00%
NaN%
Inozyme Pharma Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.35
-$0.29
-$0.33
-$0.38
-
Expected
-$0.43
-$0.32
-$0.32
-$0.36
-$0.39
Surprise
-19.17%
-8.31%
3.59%
5.56%
-
Inozyme Pharma News
AllArticlesVideos
Inozyme Pharma Publishes Preclinical Data Supporting INZ-701 as a Potential Therapy for a Broad Range of Serious Rare Diseases Impacting Bone Health and Blood Vessel Function
GlobeNewsWire·2 days ago
Inozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency
GlobeNewsWire·4 weeks ago
Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children's Bone Health (ICCBH)
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inozyme Pharma stock?
Inozyme Pharma (INZY) has a market cap of $358M as of July 27, 2024.
What is the P/E ratio for Inozyme Pharma stock?
The price to earnings (P/E) ratio for Inozyme Pharma (INZY) stock is 0 as of July 27, 2024.
Does Inozyme Pharma stock pay dividends?
No, Inozyme Pharma (INZY) stock does not pay dividends to its shareholders as of July 27, 2024.
When is the next Inozyme Pharma dividend payment date?
Inozyme Pharma (INZY) stock does not pay dividends to its shareholders.
What is the beta indicator for Inozyme Pharma?
Inozyme Pharma (INZY) has a beta rating of 1.54. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Inozyme Pharma stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.